BioSpace News Archive

LTS LOHMANN Therapie-Systeme AG announced that its customer Coherus BioSciences, Inc has launched its UDENYCA® on-body injector utilizing the LTS Sorrel™ wearable drug delivery platform.) UDENYCA® is a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Chief Executive Officer Dr. Matt Coffey will present a corporate overview at the Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference.

Lavie Bio Ltd. Ltd. announced that it has successfully secured the second-half advance payment of $2.5 million after meeting Corteva’s (NYSE: CTVA) licensing agreement requirements.

Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery. Ginkgo has acquired Reverie’s infrastructure and software for training large-scale AI foundation models.

Xeris Biopharma Holdings, Inc. today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024.

G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the fourth quarter and full year ended December 31, 2023.

Kamada Ltd. announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2023, as well as provide 2024 financial guidance, prior to the open of the U.S. financial markets on Wednesday, March 6, 2024.

InspireMD, Inc. announced it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open.

Fulgent Genetics, Inc. today announced financial results for its fourth quarter and full year ended December 31, 2023.

Geron Corporation today reported business highlights and financial results for the fourth quarter and full year 2023.